This is how one ought to see, how things really are.
To be shaken out of the ruts of ordinary perception, to be shown for a few timeless hours, the outer and inner world, not as they appear to an animal obsessed with survival or to a human being obsessed with words and notions, but as they are apprehended directly and unconditionally by Mind at Largethis is an experience of inestimable value to everyone and especially to the intellectual.
These words, from Aldous Huxleys seminal book The Doors of Perception, signaled a crucial turn in the popular perception of hallucinogenic drugs and the direction of hallucinogenic drug research.
It is hard to imagine a sharper departure from the psychotomimetic paradigm than that espoused by Huxley in his book. Whereas previous research referred to the hallucinogenic phenomena as distortions and disorders, Huxley extolled the perceptual alterations of mescaline, declaring, This is how one ought to see, how things really are. While researchers noted the incoherent ramblings of patients undergoing LSD treatment, Huxley used hallucinogenic drug experiences as the basis for an articulate philosophical exploration, drawing inspiration from Meister Eckhart, the Buddha, Plato, Aquinas, Whitman, and Henri Bergson. In his view, psychedelics were not simply experimental tools that could be used to artificially induce a demented mind; Huxley recognized hallucinogens potential as tools for achieving a spiritual and philosophical experience of insurmountable value, not only for psychiatrists but also for artists, intellectuals, mystics, and anyone interested in exploring the secrets of existence.
A distinguished author and intellectual who gained international fame following the publication of his novel Brave New World, Huxleys immense enthusiasm for the intellectual and spiritual implications of hallucinogenic drugs would prove formative for the generation of psychedelic drug enthusiasts that subsequently changed the face of American society.
While researchers noted the incoherent ramblings of patients undergoing LSD treatment, Huxley used hallucinogenic drug experiences as the basis for an articulate philosophical exploration.
Relevantly, one might surmise that it was a difference in set and setting that was responsible for Huxleys new and highly divergent interpretation of hallucinogenic effects. Huxley, after all, had been an aspiring mystic for much of his life. He had cultivated a steady interest in Vedanta Hinduism since the end of the 1930s; his 1945 book The Perennial Philosophy, a comparative study of mystical traditions, argued for the universal compatibility of all spiritual systems. Huxleys unique perspective certainly contributed to the development of his perennial interpretation of the effects of psychedelics, which not only enlisted the teachings of mystics from various traditions but also interpreted the drugs as revealing a perennial type of knowledge, which he termed a Mind-at-Large. In addition, Huxleys profound interest in Eastern religions led him to his invocation of Eastern concepts and ideas as avenues through which one might explore and understand the effects of psychedelics, a thesis that had a profound impact on the subsequent exegesis of psychedelia. In sum, Huxleys religious interests placed him in the unique position of shifting the discourse by being one of the first Western thinkers to point to the potential religious importance of hallucinogens.
An additional factor that contributed to Huxleys unique set was his long-standing interest in mind-transforming substances, which ran all the way back to his early writing. By 1931, the English author had already published an essay, Wanted, a New Pleasure, in which he lamented humankinds scant advancements in fashioning new forms of pleasure over the course of the past millennia. So far as I can see, the only possible new pleasure would be one derived from the invention of a new drug, he asserted at the time. For Huxley, mind-altering drugs harbored a promise to quench a deep running thirst of human existence:
If we could sniff or swallow something that would, for five or six hours each day, abolish our solitude as individuals, atone us with our fellows in a glowing exaltation of affection and make life in all its aspects seem not only worth living, but divinely beautiful and significant, and if this heavenly world transfiguring drug were of such a kind that we could wake up the next morning with a clear head and an undamaged constitutionthen, it seems to me, all our problems (and not merely the one small problem of discovering a novel pleasure) would be wholly solved and earth would become paradise.
Read with the benefit of hindsight, these daring utopian propositions present us with an exceptionally prescient description of the 1960s psychedelic ideology epitomized in DuPonts company slogan, Better living through chemistry adopted and appropriated by the flower children some 30 years after it was first coined. It was a seed that gave birth to a whole branch of utopian psychedelic thought.
Huxleys fascination with the threat and promise of consciousness-altering chemicals constitutes a thread that runs through his writing. Brave New World features the fictional drug Soma, described in the novel as the perfect escapist drug. Huxleys Soma functions as a foremost agent for social engineering, a tool for the repression of the deeper longings and higher aspirations found in mans soul. This theme of psychochemical social engineering was further developed in Huxleys 1936 essay Propaganda and Pharmacology, which envisioned a future society subjected to a state of complacent hypnosis by the mass employment of powerful mind-control drugs. By contrast, Huxleys final work, the 1962 utopian novel Island, features another fictional drug, evidently inspired by Huxleys involvement with psychedelics. This drug, Moksha, could be seen as the mirror image of Soma: a fantastic agent for spiritual liberation that provides a full-blown mystical experience and stands at the foundation of the utopian society described in the novel.
In May 1953, psychiatrist Humphry Osmond spent a few days at the Huxley residence in Los Angeles with the author and his wife. Huxley, who was fascinated by the accounts of hallucinogenic drugs and their peculiar effects, had implored Osmond to allow him to experience these effects firsthand. Osmond was reluctant at first, worried that he might become infamous as the person who rendered the famous novelist insane. However, he eventually consented, and on May 4, 1953, Huxley had his first experience with mescaline.
The experience exceeded his wildest expectations. Huxley called it without question the most extraordinary and significant experience this side of the beatific vision. Gazing on the flower arrangement in the room, he felt that he was seeing what Adam had seen on the morning of his creation the miracle, moment by moment, of naked existence. The visual effects of the mescaline, previously labeled as distortions, turned Huxleys mind to classical art. Looking at a chair and then examining Van Goghs painting of a chair, he could not help but think that the chair Van Gogh had seen was obviously the same in essence as the chair I had seen; the folds and creases in his trousers, suddenly spectacularly detailed, seemed straight from a painting by Botticelli. He described his experiences with unbridled elation, using mystical concepts such as the Godhead and the beatific vision, and depicted a world in which mescaline and similar drugs would be used for intellectual and spiritual education. For Huxley, mescaline and drugs like it represented potential educational tools that could make it possible for young people to taste and see what they have learned about at second hand, or directly but at a lower level of intensity, in the writings of the religious or the works of poets, painters and musicians. Going back to his 1931 concept of a new drug that could salvage humanity, he wrote:
What is needed is a new drug which will relieve and console our suffering species without doing more harm in the long run than it does good in the short. Such a drug must be potent in minute doses and synthesizable. If it does not possess these qualities, its production, like that of wine, beer, spirits or tobacco will interfere with the raising of indispensable food and fibers. It must be less toxic than opium or cocaine, less likely to produce undesirable social consequences than alcohol or barbiturates, less inimical to heart and lungs than the tars and nicotine of cigarettes. And on the positive side, it should produce changes in consciousness more interesting, more intrinsically valuable than mere sedation or dreaminess, delusions of omnipotence or release from inhibitions. To most people, mescaline is almost completely innocuous. Unlike alcohol, it does not drive the taker into a kind of uninhibited action which results in brawls, crimes of violence and traffic accidents.
Mescaline was not yet the ideal drug. Huxley noted that along with the happily transfigured majority of mescaline takers there is a minority that finds in the drug only hell or purgatory. However, he was confident that modern chemistry and physiology were capable of achieving practically anything if the psychologists and sociologists will define the idea.
Huxleys Doors of Perception evoked a gamut of responses: some hostile, some sympathetic, some clearly bewildered. Several magazine writers noted that Huxleys radical ideas could easily be rejected as the fantasies of a misguided crackpot had they been presented by anyone other than the respected English author. Some magazines celebrated Huxleys proposition for a superior drug that could replace alcohol; others worried that the authors ruminations might inadvertently encourage undisciplined hordes of youths to experiment with drugs. Authors were notably disturbed by Huxleys association of the mescaline experience with Christian theology and mysticism. Stephen Siff, who has conducted an exhaustive review of media reactions to Huxleys essay, notes that Time magazine went as far as to skip the parts of Huxleys text that it considered potentially offensive to readers because of their Christian content. Particularly instructive was the response from some Central European intellectuals, who were quick to point out some of the ethical and cultural concerns that would resurface repeatedly in future discussions on psychedelics. German intellectual Thomas Mann described the book as a new and particularly scandalous stage of Huxleys escapism, arguing that Huxleys sympathetic treatment of experimentation with hallucinogens amounted to an encouragement to the youth of America to engage in doping, which they do not at all need. Another scathing critique came from Swiss psychoanalyst Carl Gustav Jung.
Huxleys Doors of Perception evoked a gamut of responses: some hostile, some sympathetic, some clearly bewildered.
In an April 1954 letter to Dominican priest Victor Francis White, Jung opined that there is no point in wishing to know more of the collective unconscious than one gets through dreams and intuitions. The renowned psychiatrist acknowledged the interest of mescaline, yet he was suspicious of experiencing it himself for fear of doing so out of idle curiosity. I should hate the thought that I had touched on the sphere where the paint is made that colours the world, where the light is created that makes shine the splendour of the dawn, the lines and shapes of all form, the sound that fills the orbit, the thought that illuminates the darkness of the void, he stated. In Jungs response, one can identify an often subterranean but nevertheless recurring notion in the LSD debate, one that frames the drugs ability to elicit spiritual experiences as an artificial and therefore immoral shortcut, defying celestial mandates. I am profoundly mistrustful of the pure gifts of the Gods. You pay very dearly for them, Jung warned, enlisting Virgils Aeneid to his side: (Men of Troy, beware the horse!) Whatever it is, I fear the Greeks, even bearing gifts. As for Huxley, he was described by Jung as a Zauberlehrling, a sorcerers apprentice who has learned how to call on ghosts but does not possess the knowledge needed to control them. It would be rash to proceed any further, the psychiatrist argued, before fully understanding the unconscious.
Though seldom fully articulated, Jungs negative estimation of Huxleys new pursuit was characteristic of many others opinions voiced on both sides of the Atlantic. The English author had become a suspicious eccentric in the eyes of many, a situation that he lamented with great bafflement and bitterness. However, as the years progressed, Huxleys views proved to be highly influential with a new generation of hallucinogenic drug researchers, as well as with the nascent psychedelics movement.
Ido Hartogsohn is Assistant Professor in the Graduate Program in Science, Technology, and Society at Bar Ilan University. He is the author of American Trip, from which this article is excerpted.
Original post:
When Aldous Huxley Opened the Doors of Perception - The MIT Press Reader
- Review: Tripping on Utopia Complicates the History of Psychedelics - AOL - March 16th, 2024 [March 16th, 2024]
- Psychedelics Are Going Mainstream. Investing in Them Hasn't. - The Wall Street Journal - January 7th, 2024 [January 7th, 2024]
- Another Study Shows African Psychedelic Plant Ibogaine Treats Traumatic Brain Injury in Vets With 'Dramatic' Results - Good News Network - January 7th, 2024 [January 7th, 2024]
- Massachusetts Lawmakers Will Be Forced To Consider Psychedelics Legalization Measure That Activists Petitioned ... - Marijuana Moment - January 5th, 2024 [January 5th, 2024]
- VA to begin researching psychedelics as treatment option for veterans - Government Executive - January 5th, 2024 [January 5th, 2024]
- VA Is Funding New Research On Psychedelics' Benefits For Veterans With PTSD And Depression - Marijuana Moment - January 5th, 2024 [January 5th, 2024]
- VA ramps up study of psychedelic to treat PTSD - The American Legion - January 5th, 2024 [January 5th, 2024]
- Scientists predict DMT trip from cardiac activity - Big Think - January 5th, 2024 [January 5th, 2024]
- If psychedelics heal, how do they do it? | Proceedings of the National Academy of Sciences - pnas.org - January 5th, 2024 [January 5th, 2024]
- Psychedelics for acquired brain injury: a review of molecular mechanisms and therapeutic potential | Molecular ... - Nature.com - January 5th, 2024 [January 5th, 2024]
- U.S. Rep. Correa supports using psychedelics to treat veterans with PTSD - New Santa Ana - January 5th, 2024 [January 5th, 2024]
- DEA Confirms That Psychedelic Mushroom Spores Are Federally Legal Prior To Germination - Marijuana Moment - January 5th, 2024 [January 5th, 2024]
- Psychedelics for Psych Conditions Made Their Mark in 2023 - Medpage Today - January 5th, 2024 [January 5th, 2024]
- 2023: A Good Trip Around the Sun for Psychedelics - The National Law Review - January 5th, 2024 [January 5th, 2024]
- Understanding the Role of the FDA in Advancing Psychedelic Therapy - Medriva - January 5th, 2024 [January 5th, 2024]
- MAPS PBC Closes $100m Series A, Rebrands to Lykos Therapeutics - Psychedelic Alpha - January 5th, 2024 [January 5th, 2024]
- Closing the innovation gap: Advancing psychedelic therapy and medicines in EU mental health care - Open Access Government - January 5th, 2024 [January 5th, 2024]
- The Austin Chronic: SXSW Is High on Psychedelics, as Cannabis Programming Wanes - Austin Chronicle - January 5th, 2024 [January 5th, 2024]
- This Forgotten Psychedelic Could Revolutionize Traumatic Brain Injury Treatment - Inverse - January 5th, 2024 [January 5th, 2024]
- A 'milestone' for psychedelics: Pentagon directed to study alternative treatments for veterans - Washington Times - January 5th, 2024 [January 5th, 2024]
- Psychedelic Drugs Are Rushing Towards Approval for Therapy. Here's What's Next - Singularity Hub - January 5th, 2024 [January 5th, 2024]
- The top 8 psychedelic books you need to read | GreenState - GreenState - January 5th, 2024 [January 5th, 2024]
- Lykos Therapeutics Secures $100M in Series A Funding, Rebrands from MAPS PBC - Green Market Report - January 5th, 2024 [January 5th, 2024]
- DEA Calls For Even More THC, Psilocybin And DMT To Be Produced For Research In 2024 - Marijuana Moment - January 5th, 2024 [January 5th, 2024]
- Here's What You Missed in Cannabis, Psychedelics This Week - TipRanks.com - TipRanks - January 5th, 2024 [January 5th, 2024]
- You're not tripping: State and local leaders give psychedelics another chance - Route Fifty - December 22nd, 2023 [December 22nd, 2023]
- Are Consciousness-Expanding Psychedelics Like Psilocybin More Effective Than Prozac, Zoloft, Xanax, and Other ... - Nautilus - December 22nd, 2023 [December 22nd, 2023]
- RFK, Ramaswamy And Williamson Push Psychedelics Reform On Presidential Campaign Trail - Marijuana Moment - December 22nd, 2023 [December 22nd, 2023]
- Peyote is the darling of the psychedelics renaissance. Indigenous users say it co-opts a sacred way of life - The Guardian US - December 22nd, 2023 [December 22nd, 2023]
- USask researchers explore untold history of psychedelics - News - University of Saskatchewan - USask News - December 22nd, 2023 [December 22nd, 2023]
- California Governor Says Psychedelics Have 'Profound' Healing Potential, But He's Undecided On Legalization Bill As ... - Marijuana Moment - September 25th, 2023 [September 25th, 2023]
- As psychedelic-assisted therapy grows, so does interest from a new group: chaplains - NPR - September 25th, 2023 [September 25th, 2023]
- This Maine City Moves Unanimously On Decriminalizing Psychedelics: Focus On Public Health - Benzinga - September 25th, 2023 [September 25th, 2023]
- Tech Leaders Are Finding Balance Through Microdosing Psychedelics - The Dales Report - September 25th, 2023 [September 25th, 2023]
- Chronic Pain Can Be Treated by Psychedelics, Survey Suggests - Psychedelic Spotlight - September 25th, 2023 [September 25th, 2023]
- Insights Into the First Psychedelic-Assisted Therapy Guidelines With ... - Psychedelic Spotlight - September 25th, 2023 [September 25th, 2023]
- Living with long-term cancer is depressing. Texas doctors say psychedelics could help - The Hill - July 19th, 2023 [July 19th, 2023]
- Couples Are Doing MDMA and Ketamine Therapy To Save Their Relationships - VICE - July 19th, 2023 [July 19th, 2023]
- The Way People Are Using Psychedelics Is Changing Amid Reform ... - Marijuana Moment - July 19th, 2023 [July 19th, 2023]
- [WATCH] Turn on, tune in, legalise: Could psychedelics be next in ... - MaltaToday - July 19th, 2023 [July 19th, 2023]
- Will Psychedelics Be Rescheduled After FDA Approval? - Harris Bricken - July 19th, 2023 [July 19th, 2023]
- The Psychedelic Preparedness Scale: A Tool to Optimize Trip ... - Filter - July 19th, 2023 [July 19th, 2023]
- How to Test Psychedelics for Adulterants with Testing Kits - Psychedelic Spotlight - July 19th, 2023 [July 19th, 2023]
- Cannabis Science Conference to debut in Providence, R.I., with ... - GlobeNewswire - July 19th, 2023 [July 19th, 2023]
- New Speaker Rivas weighs in on psychedelics, housing and health care worker minimum wage - Yahoo News - July 19th, 2023 [July 19th, 2023]
- TDR's Top 5 Psychedelic Developments For The Week Of July 10 - The Dales Report - July 19th, 2023 [July 19th, 2023]
- Psychedelic Treatment with Psilocybin Relieves Major Depression, Study ... - February 20th, 2023 [February 20th, 2023]
- Johns Hopkins Launches Center For Psychedelic Research - February 20th, 2023 [February 20th, 2023]
- Psilocybin Treatment for Major Depression Effective for Up to a Year ... - February 20th, 2023 [February 20th, 2023]
- Inside the Johns Hopkins Psilocybin Playlist - Hopkins Medicine - February 20th, 2023 [February 20th, 2023]
- Research Story Tip: Psychedelic Drug Psilocybin Tamps Down Brains Ego ... - February 20th, 2023 [February 20th, 2023]
- Psychedelics: Risks, benefits, and more - Medical News Today - February 18th, 2023 [February 18th, 2023]
- Psychedelic Drug Effects, Side Effects & Dangers - January 25th, 2023 [January 25th, 2023]
- Psychedelics Decriminalization Project In Berkeley, Cal Includes ... - January 6th, 2023 [January 6th, 2023]
- Ancient mummified child was drugged with psychedelics before ritual ... - December 14th, 2022 [December 14th, 2022]
- The therapeutic potential of psychedelics - Science - December 14th, 2022 [December 14th, 2022]
- Changing Lives with Psychedelics: How Connecticut researchers are using magic mushrooms to help people overcome depression, OCD - WTNH.com - November 19th, 2022 [November 19th, 2022]
- Penis Envy Mushroom | Legal Psychedelics | Magic Mushroom - November 7th, 2022 [November 7th, 2022]
- Psychedelics. Discussing natural and synthetic friends. Science, News ... - November 5th, 2022 [November 5th, 2022]
- The Harms of Psychedelics Need to Be Put Into Context - WIRED - November 5th, 2022 [November 5th, 2022]
- Packers' Aaron Rodgers says psychedelics led to his back-to-back MVP ... - October 28th, 2022 [October 28th, 2022]
- With Promise of Legalization, Psychedelic Companies Joust Over Future Profits - The New York Times - October 25th, 2022 [October 25th, 2022]
- How do psychedelics work? This brain region may explain their effects - PBS - October 21st, 2022 [October 21st, 2022]
- Why is the American right suddenly so interested in psychedelic drugs? - The Guardian - October 19th, 2022 [October 19th, 2022]
- Can Psychedelics Cure? Science Is on the Verge of Finding Out - Newsweek - October 19th, 2022 [October 19th, 2022]
- Large national survey suggests that the use of psychedelics is not associated with lifetime cancer development - PsyPost - October 19th, 2022 [October 19th, 2022]
- This Pharma Company Just Scored Another Psychedelics Patent And Set Its Sights On 70 More - Small Pharma - Benzinga - October 19th, 2022 [October 19th, 2022]
- What Made the Mushrooms Magic: Psychedelic Study Explores the Odd Evolution of Mind-Altering Fungi - The Debrief - October 19th, 2022 [October 19th, 2022]
- Psychedelics And Wellness: The Healing Company Buys PepsiCo-Backed Superfoods Company - (HLCO) - Benzinga - October 19th, 2022 [October 19th, 2022]
- What's on the Colorado ballot? Housing, psychedelics, school meals, alcohol, taxes and more | FOX31 Denver - FOX 31 Denver - October 19th, 2022 [October 19th, 2022]
- DoseConnect to Sponsor the Tech Stage at Wonderland Miami by Microdose - Benzinga - October 19th, 2022 [October 19th, 2022]
- What Is Going on With Bright Minds (DRUG) Stock Today? - InvestorPlace - October 19th, 2022 [October 19th, 2022]
- Psychedelics May Ease Fear of Death and Dying - October 17th, 2022 [October 17th, 2022]
- TDR's Top 5 Psychedelic Developments For The Week Of October 10 - The Dales Report - October 17th, 2022 [October 17th, 2022]
- DEA Wants To Boost Production Of Cannabis & Psychedelics For Research In 2023 - Benzinga - October 17th, 2022 [October 17th, 2022]
- Talk set to explore psychedelics and mental health - Reading Today - October 17th, 2022 [October 17th, 2022]
- Silo Wellness Closes Acquisition of Dyscovry Science and Its Psilocybin Pharmaceutical Biosynthesis and Research Portfolio - Yahoo Finance - October 17th, 2022 [October 17th, 2022]
- How does psilocybin rewire the brain? - Open Access Government - October 17th, 2022 [October 17th, 2022]
- HYTN Awarded Controlled Drugs and Substances Dealers License Allowing for Production and Sale of Psilocybin - Yahoo Finance - October 17th, 2022 [October 17th, 2022]
- The Healing Company acquires leading superfoods business, Your Super, and lands $150M credit facility to expand community of brands - Yahoo Finance - October 17th, 2022 [October 17th, 2022]